MedTrace Logo

Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors

NCT00019630 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2024-03-04

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase I trial to study the effectiveness of liposomal doxorubicin in treating children who have refractory solid tumors.

Conditions

  • Childhood Soft Tissue Sarcoma
  • Childhood Liver Cancer
  • Bone Cancer
  • Brain Tumor
  • Kidney Tumor

Interventions

DRUG

doxorubicin HCl liposome

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Elizabeth Lowe · National Cancer Institute (NCI)

Study Design

Purpose
TREATMENT

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00019630 on ClinicalTrials.gov